Cases with primary central nervous system (CNS) tumors and metastases in advanced stages, where established therapies are exhausted, are regularly discussed for a possible inhibitory antibody treatment against BRAF V600E mutated tumor cells. This evidence concerns the gene BRAF and central nervous system neoplasm.